Literature DB >> 8077332

Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone beta subunit response to thyrotropin-releasing hormone.

L Daneshdoost1, T A Gennarelli, H M Bashey, P J Savino, R C Sergott, T M Bosley, P J Snyder.   

Abstract

Because of the recent finding that a majority of clinically nonfunctioning pituitary macroadenomas in women could be identified as of gonadotroph origin by their LH beta-subunit responses to TRH, we evaluated in this study the value of the LH beta-subunit response to TRH in identifying gonadotroph adenomas in men with clinically nonfunctioning macroadenomas. Thirty-eight consecutively studied men with clinically nonfunctioning macroadenomas were given TRH iv, and intact FSH and LH and LH beta- and alpha-subunits were measured every 15 min for 90 min before and 90 min after. TRH tests were also performed on 15 healthy, age-matched control men and on 12 men with adenomas secreting GH or PRL. Of the 38 men with clinically nonfunctioning macroadenomas, basal values were supranormal in 10 for FSH and in 6 each for alpha- and LH beta-subunits. Responses to TRH were elevated, compared to the healthy, age-matched controls, in 14 for LH beta-subunit and in 5 each for intact FSH and LH. None of the men with adenomas secreting GH or PRL exhibited supranormal responses to TRH. Of the 38 clinically nonfunctioning adenomas, 35 were established in dispersed cell culture, and 29 secreted readily detectable amounts of intact FSH, LH, and LH beta-subunit, strongly suggesting that these adenomas were of gonadotroph cell origin. We conclude that the LH beta-subunit response to TRH can identify gonadotroph adenomas in men with clinically nonfunctioning adenomas better than can basal concentrations of intact FSH and alpha-subunit, alone or combined, but not as well as it can in women.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8077332     DOI: 10.1210/jcem.77.5.8077332

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

Review 1.  Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas.

Authors:  Mansur E Shomali; Laurence Katznelson
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 2.  Silent (clinically nonfunctioning) pituitary adenomas.

Authors:  Sarah E Mayson; Peter J Snyder
Journal:  J Neurooncol       Date:  2014-03-28       Impact factor: 4.130

3.  TRH is a tonic secretagogue in growth hormone secreting but not in nonfunctioning pituitary tumors.

Authors:  D Somjen; K Tordjman; Y Greenman; F Kohen; G E Ouaknine; N Stern
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

4.  GH-, PRL-, POMC-, beta-TSH-, beta-LH-, beta-FSH-mRNA in gonadotroph adenomas of the pituitary by in situ hybridization in comparison with immunostaining and clinical data.

Authors:  A Münscher; M Schmid; W Saeger; S Schreiber; D K Lüdecke
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

5.  Immunodetection of glycoprotein hormone subunits in nonfunctioning and glycoprotein hormone-secreting pituitary adenomas.

Authors:  K Saccomanno; M Bassetti; A Lania; M Losa; G Faglia; A Spada
Journal:  J Endocrinol Invest       Date:  1997-02       Impact factor: 4.256

Review 6.  Clinically non-functioning pituitary adenoma.

Authors:  Craig A Jaffe
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

7.  Pancreastatin secretion by pituitary adenomas and regulation of chromogranin B mRNA expression.

Authors:  L Jin; B W Scheithauer; W F Young; D H Davis; G G Klee; R V Lloyd
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

Review 8.  Endocrine inactive and gonadotroph adenomas: diagnosis and management.

Authors:  M Losa; P Mortini; R Barzaghi; A Franzin; M Giovanelli
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

9.  Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline.

Authors:  T Lohmann; C Trantakis; M Biesold; S Prothmann; S Guenzel; R Schober; R Paschke
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

10.  Serum FSH bioactivity and inhibin levels in patients with gonadotropin secreting and nonfunctioning pituitary adenomas.

Authors:  S Borgato; L Persani; R Romoli; D Cortelazzi; A Spada; P Beck-Peccoz
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.